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Multiple myeloma (MM) remains incurable despite novel therapies, suggesting the need for further identifica-
tion of factors mediating tumorigenesis and drug resistance. Using both in vitro and in vivo MM xenograft
models, we show that plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) microenvironment
both mediate immune deficiency characteristic of MM and promote MM cell growth, survival, and drug resis-
tance. Microarray, cell signaling, cytokine profile, and immunohistochemical analysis delineate the mecha-
nismsmediating these sequelae. Although pDCs are resistant to novel therapies, targeting Toll-like receptors
with CpG oligodeoxynucleotides both restores pDC immune function and abrogates pDC-induced MM cell
growth. Our study therefore validates targeting pDC-MM interactions as a therapeutic strategy to overcome
drug resistance in MM.INTRODUCTION
Multiple myeloma (MM) is diagnosed in 15,000 new individuals
annually. The median survival has been prolonged from 3–4 to
7 years, especially in patients younger than age 50 (Brenner
et al., 2008; Kumar et al., 2008). However, despite important
advances, such as the biological agents bortezomib, thalido-
mide, and lenalidomide, MM remains incurable due to the devel-
opment of drug resistance, which manifests as relapsed/refrac-
tory disease (Anderson, 2007). The molecular mechanisms
whereby MM cells evade drug-induced cytotoxicity and acquire
drug-resistant phenotypes include interaction of MM cells with
their bone marrow (BM) microenvironment (Dalton and Ander-
son, 2006; Hideshima et al., 2007). The BM milieu containsstromal cells (BMSCs), osteoclasts (Roodman, 2008), myeloid
cells, and immune effector cells. BMSCs promote growth and
drug resistance in MM cells; however, the functional significance
of other BM cellular components is unclear.
Macrophages and dendritic cells (DCs) regulate tumor cell
growth (Banchereau and Steinman, 1998; Kukreja et al., 2006;
McKenna et al., 2005; Ribatti et al., 2006). DCs are BM-derived
mononuclear cells (MNCs) that also play an essential role in
immune responses (Steinman and Cohn, 1973). In humans,
two major DC subsets have been identified based on their origin,
phenotype, and function (Colonna et al., 2004; O’Doherty et al.,
1994): myeloid DCs (mDCs) (CD11c+, CD123) that include
Langerhans cells and interstitial DCs, and plasmacytoid
dendritic cells (pDCs) (Grouard et al., 1997). pDCs lack lineageSIGNIFICANCE
Recent reports demonstrate infiltration of dendritic cells (DCs) at tumor sites, but with unclear significance. Here we show
the pathophysiologic role of plasmacytoid DCs (pDCs) in multiple myeloma (MM). Our study shows increased numbers and
more frequent localization of pDCs in MM patient BM than normal BM. Functional analysis using in vitro and in vivo models
of human MM in the BM milieu shows that pDCs confer growth, survival, chemotaxis, and drug resistance. Importantly,
targeting Toll-like receptors with CpG ODNs improves immune function of pDCs and abrogates pDC-induced MM cell
growth. These findings identify an integral role of pDCs in MM pathogenesis and provide the basis for targeting pDC-MM
interactions as therapeutic strategy to improve patient outcome.Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc. 309
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pDC-MM Interactions: A Therapeutic Target in MMFigure 1. Distribution and Frequency of pDCs
(A) Total MNCs were subjected to BDCA-4-positive selection with two-step purification, and then labeled with CD123 PE-Cy5, HLA-DR Pacific Blue, BDCA-2
FITC, CD14-PE, CD20 PE, CD11c, and CD3 APC antibodies. Lin, and CD11c (90%) cells were gated and FACS sorted. Analysis of this cell population showed
99% BDCA-2+, 98% HLA-DR+, and 98% CD123+ cells.
(B) DNA synthesis in allogeneic T cells stimulated by pDCs from healthy donors and MM patients (mean ± standard deviation [SD]; n = 4).
(C) IHC analysis on normal donor BM and MM patient BM biopsies was performed using BDCA-2 antibody. Arrows indicate brown BDCA-2-positive pDCs. Micro-
graphs are representative from ten MM patients and five normal donors. Scale bars represent 10 mM.
(D) Quantification of BDCA-2-positive pDCs in MM BM versus normal BM from (C). The pDC frequency was quantified by selecting five random independent high-
power (340) microscopic fields for each tissue sample.
(E) Quantification of pDCs from normal donors PB and BM versus MM patient PB and BM by FACS using BDCA-2-PE conjugated antibody. In the upper panel,
data shown were derived from analysis of 32 MM patients and 8 normal donors. In the lower panel is a representative FACS analysis showing a higher percentage
of BDCA-2-positive pDCs in MM BM versus normal BM.
(F) The upper panel shows quantification of pDCs from matched paired samples of eight MM patient PB and BM by FACS using BDCA-2 antibody. In the lower
panel, a representative FACS analysis from eight patients analyzed is shown. Error bars indicate SD.cell markers for T, B, NK cells, and monocytes, and express
CD123, HLA-DR, and BDCA-2 (Colonna et al., 2004; Dzionek
et al., 2002; Grouard et al., 1997; O’Doherty et al., 1994). Stimu-
lated pDCs have strong antigen-presenting potential, and regu-
late antiviral innate immunity (Gilliet et al., 2008; Krieg, 2007;
Siegal et al., 1999). Prior studies showed that pDCs from MM
patients are defective in their antigen-presenting function
(Brimnes et al., 2006; Ratta et al., 2002). Indeed, loss of immune
function of tumor-infiltrating DCs has been linked to the suppres-
sive effects of the tumor microenvironment mediated via
vascular endothelial growth factor (VEGF), interleukin-6 (IL-6),
or macrophage stimulating factor (MCSF) in cancers (Zou,
2005), including MM (Hayashi et al., 2003). Importantly, pDCs
play a role in normal B cell development into plasmablasts, their
differentiation into antibody-secreting plasma cells, and their
survival (Garcia De Vinuesa et al., 1999; Jego et al., 2003; Poeck
et al., 2004; Tabera et al., 2008). However, the role of pDCs in
regulating growth and survival of malignant plasma cells is
unclear. In the present study, we have characterized the distribu-
tion/frequency and function of pDCs in MM.310 Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc.RESULTS AND DISCUSSION
Distribution and Frequency of pDCs in MM
MM is characterized by immune dysfunction (Brown et al., 2001;
Ratta et al., 2002). We first examined the immune function of
pDCs derived from normal donors versus MM patients (defined
in Figure 1A as HLA-DR+ CD123+ BDCA-2+ cells) by their ability
to stimulate allogeneic T cell response. Even though resting
pDCs are known poor antigen-presenting cells (Liu, 2005),
a comparative analysis of MM BM pDCs versus normal pDCs
shows markedly decreased ability of MM BM pDCs to trigger
T cell proliferation versus normal pDCs (p = 0.01).
Recent reports linked increased infiltration of pDCs in human
tumors (Liu, 2005), but with unclear significance. Studies related
to the distribution of pDCs in MM are limited and unclear. For
example, one study observed a decreased number of pDCs in
peripheral blood (PB) from MM patients compared with PB
from normal donors (Brimnes et al., 2006), whereas another
study showed that PB-derived pDCs from MM patients are
numerically within the normal range (Brown et al., 2001). We
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in MM patients versus normal donors using immunohistochem-
ical analysis of biopsy samples and fluorescence-activated cell
sorting (FACS) analysis of freshly obtained samples. For these
studies, we utilized antibody against pDC specific marker
BDCA-2 (Dzionek et al., 2001). We examined ten MM patient
and five normal donor BM biopsy specimens for the expression
of BDCA-2 by immunohistochemistry analysis. Figure 1C is
a representative photograph showing pDCs as BDCA-2-
positive stained (brown) cells. These cells were then quantified
in all MM patient and normal samples (Figure 1D); pDCs were
increased in MM BM versus normal BM. We then utilized
FACS analysis to determine the frequency of pDCs in freshly
obtained samples using BDCA-2 antibody. We examined BM
samples from 32 MM patients with newly diagnosed and
relapsed/refractory disease, as well as samples from eight
normal donors. Comparative analysis shows 4.7% ± 0.8%
pDCs in MM BM versus 0.4% ± 0.2% in normal donor BM
(Figure 1E). In contrast, no significant difference in pDC number
was observed between normal BM versus PB (Figure 1E, eight
normal donors). Furthermore, increased pDCs were noted in
MM BM versus MM PB. Analysis of pDCs in matched BM and
PB samples from eight patients confirmed increased numbers
of pDCs in BM than in PB (4.4 ± 0.3% in BM versus 0.62 ±
0.24% in PB, Figure 1F). These findings suggest that (1)
increased numbers of pDCs are present in MM patient BM
versus normal BM; and (2) pDCs are more frequently localized
in MM BM than MM PB.
pDCs Trigger Growth and Prolong Survival of MM Cells
We next examined the functional significance of increased pDC
numbers in MM BM. Our prior studies showed that BMSCs
trigger MM cell growth; therefore, we examined whether pDCs
similarly affect MM cells. MM.1S cells and normal PB pDCs
were cultured either alone or together at 1:3, 1:5, or 1:7
(pDC:MM) ratio for 24 hr, 72 hr, and 120 hr, and DNA synthesis
was measured by 3H-thymidine (3H-Tdr) uptake. A significant
increase in DNA synthesis was noted when MM cells were
cultured with pDCs at 1:5 (pDC/MM) ratio: for example, a 3- to
4-fold increased 3H-Tdr uptake was found in MM.1S cells
cultured with pDCs for 72 hr versus control MM cells alone (p <
0.005) (Figure 2A). No increase in DNA synthesis was observed
in pDCs cultured alone (Figure 2A). Coculture of pDCs with
MM.1S cells at 1:3 or 1:7 (pDC/MM) ratio also induced MM.1S
cell growth (data not shown); however, maximal growth was
noted at 1:5 pDC/MM ratios. This 1:5 pDC/MM ratio is physiolog-
ically relevant because pDC frequency in MM BM is 4.7% ±
0.8% (Figure 1E) corresponding to 23.5% ± 3% MM cells in
BM. Coculture of green fluorescent protein (GFP)-expressing
MM.1S cells with pDCs increased number of GFP+ cells, sug-
gesting that pDCs induce MM.1S cell growth (Figure 2B). Irradi-
ated pDCs retain their ability to trigger MM cell proliferation
(Figure 2C). To determine whether pDCs alter the clonogenic
growth of MM cells, we plated MM.1S cells with pDCs in meth-
ylcellulose cultures. pDCs markedly increase the number of
tumor colonies versus tumor cells alone (Figure 2D). This MM
cell growth promoting activity of pDCs was further confirmed
by additional assays. For example, WST proliferation assay
also showed that pDCs trigger proliferation of MM cells(Figure 2E). Finally, pDC-induced MM cell growth was associ-
ated with activation of growth signaling kinase ERK in MM.1S
cells (Figure 2F). Together, these findings demonstrate that
pDCs can promote MM cell growth.
Our prior studies showed that BMSCs trigger MM cell growth
(Hideshima et al., 2007). A recent study showed that in vitro-
generated mDCs enhance clonogenicity of MM cells (Kukreja
et al., 2006). We therefore examined the stimulatory effect of
normal PB mDCs versus pDCs versus MM patient BMSCs on
MM cell growth. Culture of MM.1S cells with BMSCs triggered
a 2.2 ± 0.7-fold increase in DNA synthesis in MM.1S cells. Impor-
tantly, pDCs triggered 3.1 ± 0.3-fold increased DNA synthesis,
whereas mDCs induced only 15%–20% increased DNA
synthesis (Figure 2G). These data suggest that BMSCs and
mDCs also stimulate DNA synthesis, albeit to a lesser extent
than pDCs. The differences in the potency of pDC versus
mDCs in our study versus a previous report (Kukreja et al.,
2007) may be due to the use of different MM cell line, sources
of pDCs, and/or growth assays. Nonetheless, both studies
suggest a role of DCs in modulating MM cell growth. Addition-
ally, pDCs are more robust growth stimulators of MM cells
than monocytes under similar experimental conditions (see
Figure S1 available online). Importantly, the pDC-depleted BM
cells did not trigger significant DNA synthesis in MM cells
(Figure 2H). Similarly, coculture of pDC-depleted BM cells with
GFP-MM.1S cell showed no increase in GFP+ cell numbers
(data not shown), confirming the specific MM cell growth-
promoting activity of pDCs.
Genetic heterogeneity (Bergsagel and Kuehl, 2005) and drug
resistance in MM impact the interaction of tumor cells with
BMSCs and its functional sequelae (Hideshima et al., 2007). We
examined the growth-promoting activity of pDCs in a broader
panel of MM cell lines, including those that are drug resistant
and cytogenetically distinct. These included Dex-resistant
MM.1R cell line with t14;16 translocation; parental RPMI-8266
cell line and its doxorubicin-resistant derivative (8226/Dox-6);
an IL-6-dependent cell line INA-6; and OPM-2 (t4:14) MM cell
line. pDCs stimulated DNA synthesis in all MM cell lines, albeit
to a differential extent (Figure 2I). These findings suggest that
genetic heterogeneity in MM may be associated with differential
tumor growth responses to pDCs.
Patient MM cells have a low proliferative capacity in vitro, and
we similarly examined the effects of pDCs on primary tumor
cells. Our results show that pDCs trigger proliferation of patient
MM cells (Figure 3A), evidenced by increase in DNA synthesis.
In contrast, pDCs had little, if any, effect on DNA synthesis in
normal plasma cells (Figure 3A). Similar results were obtained
with viability assays (data not shown).
We next examined whether MM patient pDCs, like normal
donor pDCs, trigger proliferation of MM cell line and patient
MM cells. MM patient-derived BM pDCs induced growth of
both allogeneic MM.1S cell line (Figure 3B), and autologous
tumor cells (Figure 3C). Importantly, we found a significant
increase in the survival of patient MM cells when cocultured
with pDCs for 3–4 weeks (Figure 3D; 35%–50% increase in
five of five patients cells, p < 0.05). Immunostaining with
kappa and lambda immunoglobulin G (IgG) antibodies confirmed
the clonality of MM cells in prolonged cultures with pDCs
(Figure 3E).Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc. 311
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pDC-MM Interactions: A Therapeutic Target in MMFigure 2. pDCs Induce MM Cell Growth
(A) MM.1S cells (5 3 104 cells/200 ml) and pDCs (1 3 104 cells/200 ml) were cultured either alone or together for indicated intervals, and then analyzed for DNA
synthesis using 3H-TdR uptake (mean ± SD; n = 3).
(B) GFP+ MM.1S cells were cultured either alone or with pDCs for 3 days; GFP+ MM.1S cells were counted under fluorescent microscope (mean ± SD; n = 2). The
inset shows a micrograph from the experiment (scale bars represent 40 mM).
(C) MM.1S cells were cultured alone or together with either irradiated or nonirradiated pDCs for indicated intervals, and analyzed for growth (mean ± SD; n = 2).
(D) MM.1S cells were plated with or without pDCs. The numbers of tumor colonies were enumerated using microscopy after incubation for 10–14 days (mean ±
SD; n = 2).
(E) MM.1S cells and pDCs were cultured as in (A) for 72 hr and analyzed for growth by WST assays (mean ± SD; n = 3).
(F) MM.1S cells (2.53 106) and pDCs (0.53 106) were cultured as in (A); MM.1S cells were separated from pDC cocultures with CD138 microbeads and analyzed
for ERK activation by immunoblotting.
(G) MM.1S cells, pDCs, mDCs, or MM patient-BMSCs were cultured either alone or together at 1:5 (pDC/MM, mDC/MM or BMSC/MM) ratio for 3 days, and DNA
synthesis was measured using 3H-TdR uptake (mean ± SD; n = 3).
(H) pDC-depleted MM BM cells versus purified MM BM pDCs were examined for their stimulatory effect on MM.1S cell growth (mean ± SD; n = 2).
(I) MM cell lines were cultured either alone or together with pDCs for 3 days, and analyzed for DNA synthesis by 3H-TdR uptake assay. Data are presented as fold
change in DNA synthesis in the presence versus absence of pDCs (mean ± SD; p < 0.05; n = 3). Normal PB pDCs were utilized in experiments shown in (A)–(I).
Cocultures of pDCs and MM cells were performed using 1:5 (pDC/MM) ratio. Growth assays were performed using 13 104 pDCs and 53 104 MM cells in 200 ml
media in 96-well plates. Error bars indicate SD.pDCs Confer Drug Resistance
Binding of MM cells to BMSCs mediates resistance to conven-
tional (dexamethasone) therapies; and conversely, novel thera-312 Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc.pies (bortezomib, lenalidomide) can overcome this growth
advantage conferred by BMSCs (Hideshima et al., 2007). We
therefore next determined whether various anti-MM agents
Cancer Cell
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(A) Purified patient MM cells and normal BM plasma cells from healthy donors were cultured with or without pDCs for 3 days, and DNA synthesis was measured by
3H-TdR uptake (mean ± SD of triplicate cultures; p < 0.05 for all samples; pDC/MM ratios: patient number (pt#) 1–3 at 1:5, pt#4 at 1:2, and pt#5 at 1:3).
(B) MM.1S cells were cultured as in Figure 2A with or without patient BM pDCs for 3 days, and analyzed for growth by 3H-TdR uptake (mean ± SD of triplicate
cultures; p < 0.005 for all samples).
(C) Patient MM cells were cultured with or without autologous BM pDCs for 3 days, and DNA synthesis was measured by 3H-TdR uptake (mean ± SD of triplicate
cultures; p < 0.004 for all samples; pDC/MM ratio: pt#1–4 at 1:5). Data (B and C) are presented as fold change in DNA synthesis in the presence versus absence of
patient BM pDCs.
(D) Normal PB pDCs and patient MM cells were cocultured in DCP-MM medium at 1:5 (pDC/MM) ratio for 3 weeks, and viable cells were quantified by trypan
blue exclusion assay. Data are presented as percent increase in survival of tumor cells in the presence versus absence of pDCs (mean ± SD of duplicate cultures;
p < 0.05).
(E) Normal PB pDCs and patient MM cells were cocultured as in (D) for 4 weeks and then stained with CD138-FITC antibody, CD123-PE antibody, kappa/lambda
antibody, and DAPI. The micrograph shown is representative of five experiments with similar results. Scale bars represent 20 mM (left three panels) and 10 mM
(right, upper, and lower panels). Error bars indicate SD.overcome pDC-mediated biologic sequelae in MM cells. We
asked (1) whether the anti-MM agent bortezomib directly affects
the viability of pDCs; and (2) whether pDC-triggered growth of
MM cells is affected by bortezomib. Treatment of normal PBpDCs for 24 hr with bortezomib (20 nM) did not significantly
decrease their viability (Figure 4A). Similarly, treatment of pDCs
with even higher doses of bortezomib (20–100 nM) did not trigger
significant apoptosis (Figure 4B). Longer periods (48 hr) andCancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc. 313
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pDC-MM Interactions: A Therapeutic Target in MMFigure 4. pDCs Confer Drug Resistance in MM Cells
(A and B) pDCs (1 3 106 cells) were treated for the indicated time and concentrations of bortezomib and then analyzed for viability and apoptosis by MTT and
Annexin V/PI staining assays (mean ± SD; p < 0.005; n = 4).
(C) MM.1S and MM.1R cells were treated with bortezomib in the presence or absence of pDCs for 24 hr, and analyzed for viability (mean ± SD; p < 0.05; n = 4).
(D) pDCs were treated with indicated agents for 24 hr, and then analyzed for viability (mean ± SD; p < 0.05; n = 3).
(E) MM.1S cells or MM.1S plus pDCs were cultured in the presence or absence of bortezomib (5 nM) or lenalidomide (5 mM), and analyzed for DNA synthesis by
3H-TdR uptake assay (mean ± SD; p < 0.05; n = 3).
(F) MM.1S cells were cultured with pDCs for 72 hr, separated with CD138 microbeads, and harvested; protein extracts were analyzed for proteasome activity.
Data are presented as percent increase in proteasome activities in the presence versus absence of pDCs (mean ± SD; p < 0.005; n = 3). Similarly, pDC-induced
alteration in protein ubiquitination in MM.1S cells was assessed by immunoblotting.
(G) MM.1S cells were cultured as in (F) and analyzed for NF-kB activity with p65 ELISA assay (mean ± SD; p < 0.05, n = 3). As shown in the inset, MM.1S cells
cultured with or without pDCs were analyzed for p-IkB levels by immunoblotting.
(H) MM.1S or MM.1R cells were cultured with pDCs in the presence or absence of PS-1145, and then analyzed for growth (mean ± SD; p = 0.01 for MM.1S and
p = 0.02 for MM.1R cells; n = 2).
(I) MM.1S cells were transfected with siRNA IKKb (0.8 mM) or scrambled siRNA for 48 hr and harvested; protein extracts were subjected to immunoblot analysis
with anti-IKKb or anti-GAPDH antibodies.
(J) MM.1S cells were transfected with siRNA IKKb or scrambled siRNA, followed by coculture with pDCs for indicated times; and then analyzed for growth using
WST proliferation assay (mean ± SD; n = 2). Normal PB pDCs were utilized in experiments shown in (A)–(J) at 1:5 pDC/MM ratio. Culture medium is described in
Experimental Procedures. Error bars indicate SD.higher dose of bortezomib triggered cell death of pDCs (data not
shown), as also reported in a prior study (Kukreja et al., 2007).
However, it is noteworthy that MM cells require many fold lesser
concentrations of bortezomib and shorter periods of exposure to
undergo apoptosis (e.g., IC50 for MM.1S cells is 5 nM at 24 hr, as
in Figures 4A and 4B), suggesting that pDCs are relatively resis-
tant to bortezomib compared to tumor cells. Importantly, and in
agreement with a previous report (Kukreja et al., 2007), we found
that pDCs protect MM cells against bortezomib-induced cyto-314 Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc.toxicity (Figure 4C). Furthermore, pDCs triggered MM cell prolif-
eration even in the presence of bortezomib, albeit to a lesser
extent than without drug (Figure 4E). As with bortezomib, treat-
ment of pDCs with immunomodulatory drug lenalidomide does
not significantly decrease their viability (Figure 4D). Moreover,
pDCs triggered increased DNA synthesis in MM cells even in
the presence of lenalidomide (Figure 4E). Conventional agent
Dex (0.5 mM) triggered only 8%–10% decreased viability of
pDCs (Figure 4D), with 12%–15% apoptosis. Importantly, similar
Cancer Cell
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cells (data not shown). We therefore conclude that in comparison
to tumor cells, pDCs are relatively resistant to bortezomib, lena-
lidomide, and Dex therapies.
We next performed microarray analysis to identify the molec-
ular mechanisms whereby pDCs confer growth and drug resis-
tance in MM cells. For these studies, we examined pDC-induced
gene changes in MM cells. In particular, we found that pDCs trig-
gered upregulation of transcripts mediating proteasome function
in MM.1S cells, including proteasome 26S subunit and PA200
(ATPase complex) (Figure S2). Furthermore, a marked increase
in chymotrypsin-like (CT-L), caspase-like (C-L), and trypsin-like
(T-L) proteasome activity, was noted in MM.1S cells cultured
with pDCs versus MM.1S cells alone (Figure 4F). In concert
with these findings, pDCs triggered a decrease in protein ubiqui-
tination in MM.1S cells (Figure 4F). Bortezomib primarily blocks
CT-L and C-L, but not T-L activity, and pDCs significantly
increase T-L activity in MM cells. Importantly, bortezomib-
induced cytotoxicity is linked to inhibition of proteasome activity
(Chauhan et al., 2005), and our data suggest that pDCs upregu-
late proteasome activity. It is therefore likely that pDCs, by
enhancing proteasome activity in MM cells, raise the IC50 of
bortezomib for MM cells. A recent study also showed that over-
expression of proteasome subunit confers resistance to borte-
zomib (Oerlemans et al., 2008). These data suggest a likely
mechanism whereby pDCs confer bortezomib resistance in
MM cells.
Besides the proteasome components, pDCs also increased
transcripts linked to nuclear factor (NF)-kB signaling pathway
in MM cells including, NF-kB activating protein and genes con-
taining NF-kB consensus binding sites in their promoter regions
(e.g., IL-6, VEGF, IL-10). NF-kB mediates growth, survival, and
drug resistance in MM cells (Chauhan et al., 1996). DNA binding
enzyme-linked immunosorbent assay (ELISA) and immunoblot-
ting confirmed pDC-induced NF-kB activation in MM.1S cells
(Figure 4G and inset). Importantly, blockade of NF-kB using
IKK inhibitor PS-1145 decreases pDC-triggered MM.1S and
MM.1R cell growth (Figure 4H). To further confirm the role of
NF-kB in mediating pDC-induced MM cell growth, we knocked
down IKKb expression in MM cells using siRNA. The functional
specificity of IKKb siRNA was evident by a marked decrease in-
protein levels of IKKb (Figure 4I). Transfection of IKKb siRNA, but
not negative-control (scrambled) siRNA, significantly inhibited
pDC-induced growth in MM.1S cells (Figure 4J). Together, these
findings suggest an obligatory role of NF-kB during pDC-
triggered MM cell growth.
Chemotaxis/Migration during pDC-MM Interaction
The frequent localization of pDCs in MM BM and their ability to
trigger MM cell growth suggest involvement of chemotaxis
between pDCs and MM cells. Time-lapse live cell imaging
demonstrates increased motility of pDCs and MM cells toward
each other, evidenced by formation of filopodia (Figure 5A
and Movie S1). In agreement with these data, Transwell insert
assays demonstrate markedly increased migration of MM.1S
cells toward pDCs (Figure 5B, left panel). Importantly, 2- to
3-fold greater numbers of MM.1S cells migrated toward super-
natants from pDC-MM cultures compared to those from
cultures of pDCs or MM.1S cells alone (Figure 5B, right panel).Crystal violet staining confirms increased numbers of MM.1S
cells migrating toward supernatants from pDC-MM cultures
(Figure 5B, micrographs). Similarly, pDCs showed increased
migration toward supernatants of pDC-MM cocultures
(data not shown). These findings demonstrate chemotaxis
between pDCs and MM cells and, importantly, show that
pDC-MM interaction further enhances secretion of chemo-
tactic factors.
Role of Soluble Factors
We next directly analyzed secretion of cytokines and chemo-
kines in supernatants from pDCs, MM.1S cells, and pDC-
MM.1S cell cocultures using cytokine bead arrays. pDC-MM
interaction triggers secretion of many known MM cell growth
and chemotactic factors (Hideshima et al., 2007) including
IL-10, VEGF, CD40L, IL-8, IL-15, IL-6, and MCP-1 or IP10
(Figures 5C–5E). We also found that pDC-MM interaction
increased IL-3 and SDF-1a (CXCL12) levels (Figure 5F). Both
IL-3 and SDF-1a mediate autocrine growth and chemotaxis in
MM cells (Hideshima et al., 2007; Lee et al., 2004). SDF-1a is
involved in in vivo migration of pDCs into tumors via its ligand
CXCR4 (Zou et al., 2001). Importantly, blockade of IL-3 or
SDF-1a with neutralizing antibodies or AMD3100 (drug tar-
geting CXCR4-CXCL12) markedly abrogates pDC-induced
MM cell growth (Figure 5G). IL-3 is a survival factor for pDCs
(Grouard et al., 1997). Our finding that MM cells secrete
low levels of IL-3 constitutively, which is markedly increased
upon interaction with pDCs explains, at least in part, pro-
longed survival of pDCs when cultured with MM cells in vitro
(Figure 3E).
We next assessed whether pDCs migrate in response to che-
mokines identified in cytokine bead arrays. Transwell insert
assays show significant chemotaxis of pDCs toward CXCL12
(SDF-1a), IL-3, CXCL10 (IP-10), CCL4 (MIP1a), CCL3 (MIP1b),
and MCP-1 (Figure 5I). These data suggest that pDC-MM inter-
action upregulates many chemokines that may allow for pDCs
migration and homing of pDCs to MM BM.
Requirement of pDC-MM Cell Contact
To determine whether cell-cell contact between pDCs and MM
cells is required, we utilized Transwell Inserts assays, immuno-
fluorescence (IFC) with confocal microscopy, and immunohisto-
chemistry (IHC) analysis. Culture of pDCs and MM cells in the
transwell system, which prevents physical interaction of pDCs
with MM cells while allowing for proximity and stimulation by
soluble factors, significantly attenuated the ability of pDCs to
trigger MM cell proliferation (Figure 6A). These findings suggest
that contact-dependent secretion of soluble factors accounts for
the majority of pDC-induced MM cell growth.
To determine whether pDCs are indeed in close proximity to
MM cells in vivo, we examined BM biopsy samples from MM
patients. Patient BM biopsies were subjected to dual IFC staining
with BDCA-2 (pDCs) and CD138 (MM cells) and DAPI. Results
demonstrates direct cell-cell contact between pDCs and MM
cells as well as clusters of pDCs with MM cells (Figure 6B). IHC
analysis with another pDC marker CD123 confirmed these data
(Figure S3).
Adhesion of MM cells to BMSCs triggers transcription and
secretion of soluble factors that mediate MM cell growth inCancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc. 315
Cancer Cell
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(A) Representative examples of frames from time-lapse imaging of pDC-MM coculture are shown to demonstrate chemotactic activity between pDCs and MM
cells, as evidenced by formation of filopodia (yellow arrowheads). Images were taken for 30 ms interval for 5–15 min. The video is available in Supplemental Data
(Movie S1).
(B) Migration assays: MM.1S cells were seeded in the upper compartment; the lower chamber contained medium alone, pDCs, MM.1S cells, supernatants from
pDCs, supernatants from MM.1S cells, or supernatants from 3 day cocultures of pDCs and MM.1S cells. The migrated cells were quantified and presented as bar
graph (mean ± SD; p < 0.005; n = 2). Micrographs shows crystal violet staining of migrated cells. Scale bars represent 40 mM.
(C–E) MM.1S cells were cultured with pDCs for 72 hr as described in Experimental Procedures; supernatants were collected and subjected to cytokine bead
arrays (mean ± SD; n = 4).
(F) MM.1S cells were cultured with or without pDCs for 72 hr; supernatants were analyzed for IL-3 and SDF-1a levels using ELISA (mean ± SD; p = 0.05 for both
IL-3 and SDF-1a; n = 5).
(G) MM.1S, INA-6 (with rhIL6 2.5 ng/ml), and MM.1R cell lines were cultured with pDCs in the presence or absence of anti-IL-3 antibody (10 ng/ml) for 72 hr, and
analyzed for growth by WST proliferation assays (mean ± SD; p < 0.005; n = 3).
(H) MM.1S cells were cultured with pDCs in the presence or absence of anti-SDF-1a (100 ng/ml) or AMD3100 (10 mM), and analyzed for growth by WST
proliferation assay (mean ± SD; p < 0.005; n = 3).
(I) Transwell insert assays showing migration of pDCs toward chemokines (described in Experimental Procedures). The indicated chemokines were added to the
lower chamber of transwells, and pDcs were allowed to migrate through 5 mM pore-size filters for 2 hr. Migrated cells were quantified in the fluid phase of the lower
chamber (mean ± SD; n = 3). Normal PB pDCs were utilized in experiments shown in (A)–(I) and cultures were at 1:5 (pDC/MM) ratio. Error bars indicate SD.a paracrine manner (Anderson, 2007). Similarly, we here found
that pDC-MM interaction upregulates many MM cell growth,
survival, and chemotactic factors. Importantly, although, MM
cells constitutively secrete factors, the direct cell-cell interaction
between pDCs and MM cells further augments the production of
cytokines and chemokines that not only confer growth, survival,
and drug resistance in MM cells, but also prolong survival of
pDCs. Together, these studies suggest a role of both soluble
factors and direct pDC-MM cell-cell contact in mediating MM
cell growth and pDC survival.316 Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc.Role of pDC-MM Cell Surface Receptor-Ligand
Interactions
The above findings implicate cell surface molecules in mediating
interactions that trigger MM cell growth/survival. Both pDCs and
MM cells express molecules that play a role in B cell differentia-
tion and serve as costimulatory molecules; e.g., BAFF/APRIL
and RANK-RANKL (MacLennan and Vinuesa, 2002; Roodman
and Dougall, 2008). Indeed, we found significantly increased
BAFF levels in MM patient versus normal donor serum
(Figure 6C), as in our previous report (Neri et al., 2007).
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(A) Transwell insert assay: Two different pore size membranes were utilized to separate cells: 0.4 mM (does not allow free passage of cells) and 8 mM (allows cell
passage). Normal PB pDC (23 104) and MM.1S cells (13 105) were added into the upper and lower chamber, respectively, and incubated for 72 hr at 37C; cells
from the lower chamber were then harvested and analyzed for growth by WST assays (mean ± SD; p = 0.001; n = 3).
(B) Analysis of MM patient BM biopsies (MM #1–MM #4) to show in vivo cell-cell contact between MM BM pDCs with tumor cells. MM patient BM biopsy spec-
imens were subjected to IFC staining for MM cells (CD138 antibody, red) and pDCs (BDCA-2 antibody, green). Nuclear staining was performed with DAPI (blue).
Slides were mounted using Vectashield with DAPI. Data shown are representative of 10 MM BM samples analyzed with similar results. Scale bars represent10 mM
(MM pt#1–4). The yellow square represents the 33 zoom areas (scale bars represent 5 mM in the upper panel and 10 mM in the lower panel).
(C) BAFF levels were analyzed in serum obtained from five normal and five MM patients with ELISA.
(D) MM.1S cells were cultured either alone or together with normal PB pDCs at 1:5 (pDC/MM) ratio in the presence or absence of BAFF inhibitor at the indicated
concentrations for 72 hr and then analyzed for growth (mean ± SD; p < 0.005; n = 3).
(E) MM.1S cells were cultured with normal PB pDCs at 1:5 pDC/MM ratio in the presence or absence of rhOPG (0.5 mg/ml), TACI-Fc (1 mg/ml), or CD28-Fc (1 mg/ml)
for 24 hr, and then analyzed for proliferation (mean ± SD; p < 0.005; n = 2). Data are presented as percent growth inhibition in pDC-induced MM.1S cell growth in
the presence of agents. Error bars indicate SD.Importantly, blockade of BAFF with either a small-molecule
inhibitor or TACI-Fc significantly abrogated pDC-induced MM
cell growth (Figures 6D and 6E, respectively). TACI-Fc alone
did not affect the viability of MM.1S cells alone (data not shown).
In contrast, inhibition of RANK-RANKL with osteoprotegerin also
decreased pDC-induced MM cell growth, albeit to a lesser
extent than inhibiting BAFF (Figure 6E). Our finding that NF-kB
mediates pDC-MM functional sequelae, together with the known
role of both BAFF and RANKL in activating NF-kB, suggests the
therapeutic potential of targeting BAFF/RANKL in MM. However,
it is very likely that other cell surface receptor-ligand interactions
are also involved in mediating pDC-MM interactions.In Vivo Validation of pDC-Induced Growth of MM Cells
with MM Xenograft Models
Having defined the functional role of pDCs in regulation of MM
biology in vitro, we next examined whether pDCs similarly affect
MM cell growth in vivo using murine xenograft models of human
MM. In order to evaluate the growth-promoting function of
human pDCs within the human BM milieu, we utilized the severe
combined immunodeficiency (SCID)-hu model (Tassone et al.,
2005), which recapitulates the human BM milieu in vivo. In this
model, MM cells are injected directly into human bone chips im-
planted subcutaneously in SCID mice, and MM cell growth is as-
sessed by serial measurements of circulating levels of solubleCancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc. 317
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(A and B) INA-6 MM cells alone (23 106 cells without IL-6), or together with pDCs (0.43 106 cells) at 1:5 (pDC/MM) ratio were injected directly into the human fetal
bone implant in SCID-hu mice, and mouse sera samples were analyzed for human sIL-6R and Ig by ELISA (mean ± SD; p < 0.05; n = 2).
(C) Human bone chips were removed from mice 30 days after injection with pDCs and INA-6 cells and immunostained with anti-BDCA-2 and anti-IL-3 antibodies.
The scale bar represents 5 mM.
(D–H) Bone sections were immunostained with antibodies against Ki-67, cyclin D1, phospho-IkB, ubiquitin, and factor VIII, and VEGFR1. Dark brown: Marker-
positive cells in all cases. Micrographs are representative of bone sections from two different mice in each group.
(E and G) Quantification of Ki-67, cyclin-D1, and factor VIII-positive cells from experiments in (D) and (H) (upper panel).
(I) MM.1S cells alone (2.53 106) or together with pDCs (0.53 106) (1:5 pDC/MM ratio) were implanted subcutaneously in mice; tumor volume was monitored every
third day (p < 0.05). Shown in the inset are tumors from mice with either MM.1S or MM.1S cells + pDC. Error bars indicate SD.human IL-6R and immunoglobulin in mouse serum. A more
robust growth of tumor occurred in mice receiving human
pDCs and INA-6 MM cells than in mice injected with INA-6 cells
alone (Figures 7A and 7B). pDCs alone did not induce tumors in
mice (data not shown). Immunostaining of implanted human
bone with BDCA-2 showed presence of viable pDCs 30 days
after the initial injections (Figure 7C). As in our in vitro results,
IL-3 was highly expressed in mice injected with pDCs plus318 Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc.INA-6 cells (Figure 7C). The observation that IL-3 is a survival
factor for pDCs, coupled with our in vitro and in vivo results,
suggests that IL-3, at least in part, facilitates prolonged survival
of pDCs in vivo in the human MM BM milieu.
We also observed an increase in Ki-67 and cyclin D1-positive
cells in human bone sections from mice engrafted with pDCs and
INA-6 MM cells compared to mice receiving INA-6 cells alone
(Figures 7D and 7E). Counterstaining of bone sections with
Cancer Cell
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MM cells (data not shown). These findings are consistent with
increased proliferation of MM cells in vivo triggered by pDCs.
Similarly, we noted a marked increase in p-IkB, a decrease in
ubiquitination, and enhanced factor VIII and VEGFR1 expression
in bone sections from mice injected with pDCs plus INA-6 cells
versus INA-6 MM cells alone (Figures 7F–7H). These in vivo
data confirm our in vitro data and suggest that pDCs trigger acti-
vation of growth, survival, and angiogenic signaling pathways in
MM cells.
We next utilized a subcutaneous model of human MM in SCID
mice to further confirm pDC-induced MM cell growth. An early
and rapid growth of tumor occurred within 12 days in mice
receiving both pDCs and MM cells, whereas similar tumor
growth was noted only at day 21 in mice injected with MM cells
alone (Figure 7I). Immunostaining showed increased IL-3 and
presence of pDCs (BDCA-2+ cells) in tumor sections from mice
receiving pDCs and MM cells versus MM cells alone (data not
shown). Together, our findings from two distinct human MM
xenograft models suggest that pDCs enhance MM cell growth
in vivo.
CpG-Containing Oligodeoxynucleotides Restore
MM Patient pDCs T Cell Response
and Block MM Cell Growth
MM is characterized by immune dysfunction, and pDCs may
contribute, at least in part, because MM patient BM-pDCs
exhibit reduced ability to induce T cell proliferation (Figure 1B).
The loss of immune functioning of tumor-infiltrating DCs has
been linked to the immunosuppressive effects of the tumor-
host microenvironment mediated via VEGF, IL-6, or MCSF in
cancers (Zou, 2005), including MM (Hayashi et al., 2003). Prior
studies showed that immune function of pDCs is mediated by
production of type I IFNs (Siegal et al., 1999), which, in turn, is
linked to expression of Toll-like receptor 7 (TLR7) and TLR9 (Gil-
liet et al., 2008; Krieg, 2007; Moseman et al., 2004; Vollmer,
2005). Other studies have targeted TLR-9 using immunostimula-
tory activities of CpG-containing oligodeoxynucleotides (CpG-
ODNs) to activate pDCs. Indeed systemic lupus erythematous
is linked to TLR-9-activated pDCs and IFN-a release (Barrat
et al., 2005; Krieg, 2007; Liu et al., 2008; Vollmer, 2005). In light
of these studies, we next examined whether treatment of MM
patient BM-pDCs with CpG-ODNs alters their T cell stimulatory
activity. Importantly, CpG-ODNs restore the ability of MM patient
BM-pDCs to trigger both allogeneic and autologus T cell prolifer-
ation (Figures 8A and 8B). Furthermore, CpGs also enhanced
IFN-a secretion from MM patient BM-pDCs (Figure 8C) and
upregulated TLR9 expression in MM BM pDCs (Figure 8D).
Prior studies showed that pDCs activated via TLR ligation,
CD40-L engagement, or HIV can modulate regulatory T cells
(Tregs) (Gilliet and Liu, 2002; Manches et al., 2008; Moseman
et al., 2004). Tregs are dysfunctional and decreased in number
in MM (Prabhala et al., 2006). CD4+CD25+FOXP3-high Tregs
can be expanded by mDCs in vitro and after injection of cyto-
kine-matured DCs in MM patients (Banerjee et al., 2006). It is
possible that activated pDCs may restore Treg homeostasis in
MM; however, the functional significance of pDCs effect on
Tregs within the human MM BM microenvironment, particularly
the biologic sequelae in MM cells, remains to be examined.We next asked whether CpG-ODNs affect pDC-induced MM
cell growth. As shown in Figure 8E, CpGs inhibit patient-BM
pDC-triggered DNA synthesis in MM.1S cells. CpGs also
blocked pDC-induced growth of MM cells lines, as assessed
by WST proliferation assays (Figure 8F). These data demonstrate
that (1) activation of pDCs with CpGs both restores their ability to
trigger T cell proliferation and reduces their MM cell growth
promoting activity; and (2) MM cell interaction with pDCs does
not require pDC activation. A recent study in the B16 mouse
melanoma tumor model also showed that CpG-activated pDCs
are capable of inducing a systemic antitumor immunity via
activation of NK cells and T cells (Liu et al., 2008). It remains to
be determined whether CpG-activated MM pDCs generate
clinically significant effective antitumor immunity in MM.
In summary, we show the pathophysiologic role of pDCs in
MM. Our findings demonstrate increased numbers and more
frequent localization of pDCs in MM patient BM than normal
BM. Both in vitro and in vivo models of human MM show that
pDCs confer growth, survival, chemotaxis, and drug resistance
in MM cells. Targeting Toll-like receptors with CpG-ODNs both
improves immune function of pDCs and abrogates pDC-induced
MM cell growth. Overall, our findings identify an integral role of
pDCs in MM pathogenesis and provide the basis for targeting
pDC-MM interactions with CpG-ODNs as a therapeutic strategy
to improve patient outcome in MM.
EXPERIMENTAL PROCEDURES
Isolation, Phenotypic Analysis, and Quantification of pDCs
All studies involving human samples were performed under IRB-approved
protocols at Dana-Farber Cancer Institute (Boston), Brigham and Womens
Hospital (Boston), and Mayo Clinic (Rochester), through which informed
consent was obtained and de-identified samples were utilized. pDCs were iso-
lated by magnetically activated cell sorting using CD304 (BDCA-4/Neuropilin-
1) microbeads kit (Miltenyi Biotec, Auburn, CA). MNCs from normal healthy
donors and MM patients were isolated by Ficoll Hypaque density gradient
centrifugation. Cells were then magnetically labeled with anti-BDCA-4 anti-
body coupled to colloidal paramagnetic microbeads and passed through
a magnetic separation column twice (Miltenyi Biotec). The cells staining
negative for lineage markers and CD11c were FACS sorted (Figure 1A). Poly-
chromatic staining of cells with CD123 PE-Cy5, HLA-DR Pacific Blue, and
BDCA-2 FITC confirmed the purity of pDCs (R99%) (Dzionek et al., 2001):
BDCA-4-positive pDCs derived in this way are lineage (CD3, CD14, CD20,
CD11c-) negative, MHC II positive, and CD123/BDCA-2 positive. pDCs were
quantified in total MNCs (2 3 106 cells) from PB or BM samples using FACS
analysis (100,000 minimum events were gated) with BDCA-2 (CD303)-PE
conjugated antibody (Mitenyi Biotec). For some experiments, pDCs were puri-
fied using negative depletion (Miltenyi Biotec) (99% BDCA2+ CD123+ cells by
FACS). To obtain pDC-depleted fraction of MM BM cells, we utilized LD
columns in combination with BDCA-4 Microbeads and MACS separator (Mil-
tenyi Biotec). FACS analysis of pDC-depleted BM cell fraction showed low to
undetectable BDCA-2-positive cells (3.8% pDCs before and <0.02% pDCs
after depletion). Antibody details are in Supplemental Data. Flow cytometric
analysis was performed on a Beckman Coulter FC 500, and the data were
analyzed with CXP software (BD Biosciences, San Jose, CA).
Cell Growth, Viability, Survival, and Apoptosis Assays
Cells were cultured in complete medium (RPMI-1640 media supplemented
with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-gluta-
mine). DNA synthesis was measured by (3H)thymidine uptake (3H-Tdr) (Perki-
nElmer, Boston, MA), as previously described (Chauhan et al., 2005). Fold
change in DNA synthesis was calculated using following formula: 3H-TdR
uptake of cells in pDC-MM cultures minus 3H-TdR uptake of pDCs alone
divided by 3H-TdR uptake of MM cells alone. Growth was also assessed byCancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc. 319
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(A) Normal CD4 T cells (1 3 104) were cultured with normal pDCs or MM patient BM pDCs (1 3 105) (1:10 pDCs/T cells) in the presence or absence of CpGs for
5 days, and then analyzed for DNA synthesis (mean ± SD; n = 4).
(B) MM BM pDCs (13 104) were cultured with autologous T cells (13 105) (1:10 pDCs/T cells) in the presence or absence of CpGs (type A, 4 mg/ml) for 5 days and
then analyzed for T cell proliferation with WST proliferation assay (mean ± SD; p < 0.005 for all patients).
(C) CpG-ODNs (type A, 4 mg/ml) restore IFN-a production from MM patient BM pDCs: Both normal PB pDCs and MM patient BM pDCs (105 cells) were cultured in
the presence or absence of CpG-ODNs for 24 hr, and IFN-a levels were measured by ELISA (mean ± SD; p = 0.01, six MM patient BM pDCs and four normal pDCs
were evaluated).
(D) pDCs were cultured in the presence or absence of CpG-ODNs for 12 hr; cytospins were prepared and subjected to immunostaining with anti-TLR9 antibody
(green) and DAPI (blue). Representative micrographs from three experiments are shown. Scale bars represent 10 mM. Intracellular staining with TLR9 antibody
followed by FACS analysis shows upregulation of TLR9 expression in CpG-treated MM pDCs.
(E) CpGs block MM BM pDC-induced MM.1S cell growth. pDCs, MM.1S cells, or pDCs + MM.1S cells (1:5 pDC/MM ratio) were cultured in the presence or
absence of CpG-ODNs for 3 days, and DNA synthesis was measured with 3H-TdR uptake (mean ± SD; p < 0.004, n = 4).
(F) MM cell lines were cultured with normal PB pDCs at 1:5 pDC/MM ratio in the presence or absence of CpGs for 3 days, and then analyzed for growth by WST
proliferation assay (mean ± SD; p < 0.005, n = 4). Errors bars indicate SD.WST assay (BioVision, Mountain View, CA). Cell viability was assessed by
3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Chemicon
International Inc., Temecula, CA) assay (Chauhan et al., 2005). For cell survival
assays, pDCs and patient MM cells were cultured at 1:5 pDC/MM ratio in six-
well plates in DCP-MM culture medium (Mattek Corp. Ashland, MA). After each
week of coculture, tumor cells were separated with CD138 microbeads, and
cultured with fresh pDCs. After 4 weeks of coculture, cells were triple stained
with CD138-FITC-conjugated antibody, CD123-PE-conjugated antibody, and
DAPI, and images were taken by Zeiss LSM confocal microscope (Thornwood,
NY). Staining with kappa and lambda antibodies and DAPI confirmed clonality320 Cancer Cell 16, 309–323, October 6, 2009 ª2009 Elsevier Inc.of MM cells. Apoptosis was measured by Annexin V/PI staining (Chauhan
et al., 2005). T cell proliferation assays were performed as previously
described (Hayashi et al., 2003). Briefly, pDCs were cultured with or without
T cells, in the presence or absence of CpG-ODNS (0.4 and 4.0 mg/ml) in
complete medium; and DNA synthesis was analyzed by both 3H-TdR uptake
and WST assays.
Live-Cell Imaging
pDCs were labeled with MitoFluor Red 594 (1:1000; Invitrogen, Carlsbad, CA);
GFP-positive MM.1S were added to pDCs in a 24 well glass-bottom culture
Cancer Cell
pDC-MM Interactions: A Therapeutic Target in MMdish (MatTek Inc, Ashland, MA), and live-cell images were taken with an
Apochromat 403/1.2 W lens on a LSM-510 confocal system. Images were
taken for 30 ms interval for 5–15 min, and processed using Volocity software
(Improvision, Waltham, MA).
Immunofluorescence and Confocal Microscopy
BM biopsies from MM patients and normal donors were subjected to double
IFC staining with BDCA-2 and CD138 antibodies. Antigen retrieval was per-
formed by boiling the slides in DIVA Decloaker (Biocare, Concord CA) for
10 min in a pressure cooker. Slides were incubated with 5% normal donkey
serum, followed by staining with mouse monoclonal anti-human CD138 anti-
body (1:100) and rabbit polyclonal BDCA-2 antibody (1:10). After Tris-buffered
saline wash, slides were incubated with Alexa-488-conjugated donkey anti-
rabbit secondary antibody (1:200) and CY5 donkey anti-mouse secondary
antibody (1:200) for 1 hr at room temperature. Slides were mounted with Vec-
tashield containing DAPI (Vector Laboratories, Burlingame CA). Confocal
images were taken with the Zeiss LSM510 confocal system (633/1.4 apochro-
mat objective) (Thornwood, NY). IHC with primary antibody specific for pDCs
(BDCA-2 at 1:400 dilution) and MM cells (CD138 at 1:500 dilution) was con-
ducted in accordance with previously described methods (Jaye et al., 2006).
Transwell Migration Assays
In vitro migration assays were performed with Transwell Boyden chambers
(Chemicon, Billerica, MA). For pDC chemotaxis studies, we utilized 5 mM
pore size membranes, which allow for the free passage of pDCs. Afterward,
5 3 105 pDCs were suspended in serum-free culture medium (RPMI-1640
media supplemented with antibiotics) and plated in the upper chamber; the
lower chamber was coated with various chemokines. After 2 hr incubation at
37C, pDCs that migrated to the lower chamber were counted. pDC and
MM cell migration was assayed with a 24-well plate with 8 mm pore size inserts.
MM cells (2 3 106 cells/ml) were plated in the upper and pDCs in the lower
chamber or vice versa. Serum-free culture medium (as above) was used.
The plates were then incubated at 37C for 4 hr, and the nonmigrating cells
in the upper chamber removed from the Transwell membrane by washing
with phosphate-buffered saline. Cells migrating to the bottom face of the
membrane were stained with cresyl violet. Three randomly selected fields
were examined to quantify number of cells migrating from upper to lower
chambers. For cell-cell contact-dependent MM cell growth, we utilized two
different pore-size membranes to separate cells: 0.4 mM (that does not allow
free passage of cells) and 8 mM (that allows cell passage). pDCs (2 3 104)
and MM.1S cells (1 3 105) were added into the upper and lower chamber,
respectively, and incubated for 72 hr at 37C; cells from the lower chamber
were then harvested and analyzed for growth by WST assays.
Cytokine Bead Arrays and ELISA
MM.1S cells (5 3 104 cells/200 ml) and pDCs (1 3 104 cells/200 ml) were
cultured either alone or together at 1:5 (pDC/MM) ratio in 96 well plates for indi-
cated intervals in triplicate; supernatants were collected (a total of 600 ml for
each condition) and analyzed with human cytokine/chemokine panel-29 Plex
(Linco Diagnostic, St Charles, MO). Cells were cultured in complete medium.
BAFF, SDF1-a, and IL-3 levels were measured by Quantikine BAFF ELISA
kit (R&D Systems, Minneapolis, MN). IFN-a levels were assessed by ELISA
(PBL, Piscataway, NJ).
Proteasome Activity Assays
MM.1S cells (2.5 3 106) and pDCs (0.5 3 106) were cultured in complete
medium; MM.1S cells were separated from pDC cocultures by CD138 mi-
crobeads (purity > 99% CD138+ cells), and proteasome activity assays were
performed using fluorogenic peptide substrates, as previously described
(Chauhan et al., 2005).
Human Plasmacytoma Xenograft and SCID-hu Model
All animal experiments were approved by and conform to the relevant regula-
tory standards of the Institutional Animal Care and Use Committee at the
Dana-Farber Cancer Institute. SCID-hu model has been described previously
(Tassone et al., 2005). For SCID-hu model studies, we utilized an IL-6-
dependent INA-6 MM cell line. Cells were propagated in vitro in complete
medium, and rhIL-6 (2.5 ng/ml). INA-6 cells (23 106) without IL-6, pDCs alone(0.43 106), or INA-6 cells together with pDCs were injected directly into human
bone chips implanted subcutaneously in SCID mice. Tumor growth was
assessed every tenth day by measuring circulating levels of shIL-6R and IgG
levels in mouse blood using ELISA (R&D Systems). In the human plasmacy-
toma xenograft model, CB-17 SCID-mice were subcutaneously injected with
pDCs alone, MM.1S cells alone, or pDCs and MM.1S cells (five mice per group)
in plain RPMI-1640 medium, and tumor growth was measured as previously
described (Chauhan et al., 2005).
Immunohistochemistry
Implanted human bone chips were excised from mice and subjected to IHC
analysis with antibodies against Ki-67, cyclin-D1, p-IkB, factor VIII, VEGFR1,
and ubiquitin (Abcam, Cambridge, MA), as previously described (Singh
et al., 2006).
Statistical Analysis
Nonparametric tests and mixed models were used to analyze the data,
including Wilcoxon’s signed rank and/or Student’s t test for proliferation
assessment. Significance of differences observed in xenograft studies was as-
sessed with the Student’s t test. The minimal level of significance was p < 0.05.
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